Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation and Molecular Characterization of Colistin-Resistant Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae from the Infected Wounds of Hospitalized Patients

  • Munaza Ijaz (Department of Microbiology, University of Central Punjab) ;
  • Madiha Khan (Department of Microbiology, University of Central Punjab) ;
  • Haya Yasin (Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University)
  • Received : 2024.07.05
  • Accepted : 2024.08.06
  • Published : 2024.10.28
Download PDF
⟨ Previous Next ⟩

Abstract

This study was planned to determine the colistin-resistant (CR) gene distribution among two species of gram-negative bacteria, Pseudomonas aeruginosa and Klebsiella pneumoniae. In total, 50 isolates of K. pneumoniae (14 isolates, 28%) and P. aeruginosa (36 isolates, 72%) were isolated between August 2023 and October 2023 from clinical wound samples at Jinnah Hospital and Lahore General Hospital Lahore, Pakistan. To determine the resistance genes linked to CR and assess antimicrobial susceptibility, all isolates were kept at -80℃ in 15% glycerol broth. Using the right primer sets, a polymerase chain reaction (PCR) was utilized to identify the CR-associated mcr-1 gene of the gram-negative isolates. Out of 50, 40 isolates (80%) showed resistance against colistin with MICs of 8 and 128 ㎍/ml. The majority (97%) of P. aeruginosa CR strains were considered multidrug resistant (MDR). All K. pneumoniae isolates were resistant to cefepime, cotrimoxazole, ceftriaxone, and imipenem. The clinical CR isolates of P. aeruginosa were highly resistant to ceftriaxone, imipenem, cefepime, cotrimoxazole, ciprofloxacin, amikacin, and piperacillin/tazobactum. The antibiotic resistance pattern was terrifyingly high among both bacterial species. According to the PCR results, CR was prevalent among the gram-negative samples, and the mcr-1 gene was positive in 6/40 (15%) of the CR isolates, including four P. aeruginosa and two K. pneumoniae strains. The high CR (80%) reported in this research is cause for concern and underscores an urgent need to use colistin in a limited and logical manner, similar to other antibiotics.

Keywords

Acknowledgement

We extend our appreciation to the Deanship of Graduate Studies at Ajman University, Ajman, United Arab Emirates, for their support for payment of publication charges.

References

  1. Nation RL, Li J, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect. Dis. 6: 589-601.
  2. World Health Organization (WHO). 2018. Global Antimicrobial Resistance Surveil- lance System (GLASS) report: early implementation 2016-2017. Geneva, Switzerland: WHO, 2018.
  3. Tang SS, Apisarnthanarak A, Hsu LY. 2014 Mechanisms of β-lactam antimicrobial resistance and epidemiology of major community- and healthcare-associated multidrug-resistant bacteria. Adv. Drug Deliv. Rev. 78: 3-13.
  4. Falagas ME, Kasiakou SK, Saravolatz LD. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin. Infect. Dis. 40: 1333-1341.
  5. Kumar A, Vimal A, Kumar A. 2023. Inhibitory interaction and pharmacological analyses of berries phenolics against Listeria monocytogenes virulent protein internalin B. World J. Tradit. Chin. Med. 9: 71-80
  6. Gregoire N, Aranzana-Climent V, Magreault S, Marchand S, Couet W. 2017. Clinical pharmacokinetics and pharmacodynamics of colistin. Clin. Pharmacokinet. 56:1441-1460.
  7. Kanazawa K, Sato Y, Ohki K, Okimura K, Uchida Y, Shindo M, et al. 2009. Contribution of each amino acid residue in polymyxin B (3) to antimicrobial and lipopolysaccharide-binding activity. Chem. Pharm. Bull. 57: 240-244.
  8. Kempf I, Fleury MA, Drider D, Bruneau M, Sanders P, Chauvin C, et al. 2013. What do we know about resistance to Colistin in Enterobacteriaceae in avian and pig production in Europe? Int. J. Antimicrob Agents 42: 379-383.
  9. Gunn JS. 2008. The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol. 6: 284-290.
  10. Cannatelli A, D'Andrea MM, Giani T, Di Pilato V, Arena F, Ambretti S, et al. 2013. In vivo emergence of Colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulator. Antimicrob. Agents Chemother. 57: 5521-5526.
  11. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, et al. 2016. Emergence of plasmid-mediated Colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16: 161-168.
  12. Zurfuh K, Poirel L, Nordmann P, Nuesch-Inderbinen M, Hachler H, Stephan R. 2016. Occurrence of the plasmid-borne mcr-1 Colistin resistance gene in extended-spectrum β-lactamase-producing Enterobacteriaceae in river water and imported vegetable samples in Switzerland. Antimicrob. Agents Chemother. 60: 2594-2595.
  13. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Hoang HT, Pham NT, et al. 2016. Colistin-resistant Escherichia coli harbouring mcr-1 isolated from food animals in Hanoi, Vietnam. Lancet Infect. Dis. 16: 286 - 287.
  14. Clinical and Laboratory Standard Institute (CLSI). M100 Performance Standards for Antimicrobial Susceptibility Testing 30th ed. An Informational Supplement; CLSI: Wayne, PA, USA 2020. Available from: https://www.nih.org.pk/wp-content/uploads/2021/02/CLSI-2020.pdf
  15. Sherry N, Howden B. 2018. Emerging Gram-negative resistance to last-line antimicrobial agents fosfomycin, Colistin and ceftazidime avibactam-epidemiology, laboratory detection and treatment implications. Expert Rev. Anti Infect. Ther. 16: 289-306.
  16. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG, et al. 2006. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the infectious disease's society of America. Clin. Infect. Dis. 42: 657-668.
  17. Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P, Goossens H, et al. 2016. Identification of a novel plasmid-mediated colistin-resistance gene, mcr2, in Escherichia coli, Belgium. Euro. Surveill. 21: 130-280.
  18. Di Pilato V, Arena F, Tascini C, Cannatelli A, Henrici De Angelis L, Fortunato S, et al. 2016. MCR-1.2, a new mcr variant carried on a transferable plasmid from a colistin-resistant KPC carbapenemase-producing Klebsiella pneumoniae strain of sequence type 512. Antimicrob. Agents Chemother. 60: 5612-2615.
  19. Yang YQ, Li YX, Song T, Yang YX, Jiang W, Zhang A-Y, et al. 2017. Colistin resistance gene mcr-1 and its variant in Escherichia coli isolates from chickens in China. Antimicrob Agents Chemother. 61: e01204-e01205.
  20. Bilal H, Hameed F, Khan M A, Khan S, Yang X, Rehman TU. 2020. Detection of mcr-1 gene in extended-spectrum βlactamase-producing Klebsiella pneumoniae from human urine samples in Pakistan. Jundishapur. J. Microbiol.13: 236-376.
  21. Cheesebrough M. 2006. District laboratory practice in tropical countries. Part 2, 2nd Edition, Cambridge University Press, New York. 30-71. Available on: https://www.me
  22. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Gisake CG, et al. 2011. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microb. Infect. 18: 268-281.
  23. Zubair KU, Shah AH, Fawwad A, Sabir R, Butt A. 2019. Frequency of urinary tract infection and antibiotic sensitivity of uropathogens in patients with diabetes. Pak J. Med. Sci. 35: 1664-1899.
  24. Liu J, Zhang CC, Zhang SQ, Wang JH, Xu RR, Yang SL, et al. 2023. Clinical factors affecting platelet growth in the treatment of aplastic anemia by tonifying kidney and generating blood. World J. Tradit. Chin. Med. 9: 438-446.
  25. Liu Y, Wang Y, Walsh T, Yi L, Zhang R, Spencer J, et al. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16: 161-168.
  26. Wang J, Zhou Jy, Qu Tt, Shen P, Wei Zq, Yu Ys, et al. 2021. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int. J. Antimicrob. Agents Chemother. 35: 486-491.
  27. Peirano G, Pitout D. 2022. Extended-spectrum β-lactamase-producing Enterobacterales: update on molecular epidemiology and treatment options. Drugs 82:1477-1494.
  28. Li R, Lu X, Wang Y, et al. 2021. Occurrence of plasmid-mediated colistin resistance gene mcr-1 in clinical isolates of Klebsiella pneumoniae from China. Antimicrob. Agents Chemother. 65: 89-150.
  29. Mendes RE, Castanheira M, Wang X, et al. 2023. First report of mcr-1-mediated colistin resistance in Pseudomonas aeruginosa isolates from South America. Antimicrob. Agents Chemother. 67: 45-52.
  30. European Centre for Disease Prevention and Control (ECDC). 2022. Surveillance of antimicrobial resistance in Europe - Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC.
  31. Liu YY, Wang Y, Walsh TR, Ling-Xian Yi, Rong Zhang, James Spencer, et al. 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16: 161-168.
  32. Poirel L, Jayol A, Nordmann P. 2017. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin. Microbiol. Rev. 30: 557-596.
  33. Mohamed Abd El-Gawad El-Sayed Ahmed, Lan-Lan Zhong, Cong Shen, Yongqiang Yang , Yohei Doi, Guo-Bao Tian. 2020. Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019). Emerg. Microbes Infect. 9: 868-885.
  34. Li XY, Liang LN, Zhang WJ, et al. 2024. Mechanism of Mingjing granules in treating wet age-related macular degeneration based on network pharmacology and experimental verification. World J. Tradit. Chin. Med. 10: 22-32.